Clinical Trial Update: Interleukin-4 (IL-4) as a Marker of Atherosclerosis [NA]

View source ↗

Summary

A clinical trial evaluating interleukin-4 as a biomarker for atherosclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Ischemic Heart Disease

Snippet

Sponsor: Melbourne Health | Conditions: Atherosclerosis, Ischemic Heart Disease | NA | Status: WITHDRAWN